- Home
- AVTX vs IMMX Comparison
AVTX vs IMMX Comparison
Compare AVTX & IMMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AVTX
- IMMX
- Stock Information
- Founded
- AVTX 2011
- IMMX 2014
- Country
- AVTX United States
- IMMX United States
- Employees
- AVTX N/A
- IMMX N/A
- Industry
- AVTX Biotechnology: Pharmaceutical Preparations
- IMMX Medicinal Chemicals and Botanical Products
- Sector
- AVTX Health Care
- IMMX Health Care
- Exchange
- AVTX Nasdaq
- IMMX Nasdaq
- Market Cap
- AVTX 57.4M
- IMMX 61.1M
- IPO Year
- AVTX 2015
- IMMX 2021
- Fundamental
- Price
- AVTX $4.89
- IMMX $2.65
- Analyst Decision
- AVTX Strong Buy
- IMMX Strong Buy
- Analyst Count
- AVTX 7
- IMMX 1
- Target Price
- AVTX $31.00
- IMMX $7.00
- AVG Volume (30 Days)
- AVTX 82.2K
- IMMX 137.1K
- Earning Date
- AVTX 08-11-2025
- IMMX 08-11-2025
- Dividend Yield
- AVTX N/A
- IMMX N/A
- EPS Growth
- AVTX N/A
- IMMX N/A
- EPS
- AVTX N/A
- IMMX N/A
- Revenue
- AVTX $441,000.00
- IMMX N/A
- Revenue This Year
- AVTX N/A
- IMMX N/A
- Revenue Next Year
- AVTX N/A
- IMMX N/A
- P/E Ratio
- AVTX N/A
- IMMX N/A
- Revenue Growth
- AVTX N/A
- IMMX N/A
- 52 Week Low
- AVTX $3.39
- IMMX $1.26
- 52 Week High
- AVTX $16.00
- IMMX $3.00
- Technical
- Relative Strength Index (RSI)
- AVTX 54.89
- IMMX 61.44
- Support Level
- AVTX $4.63
- IMMX $2.16
- Resistance Level
- AVTX $5.02
- IMMX $2.80
- Average True Range (ATR)
- AVTX 0.27
- IMMX 0.17
- MACD
- AVTX 0.00
- IMMX 0.04
- Stochastic Oscillator
- AVTX 72.73
- IMMX 80.00
About AVTX Avalo Therapeutics Inc.
Avalo Therapeutics Inc is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The company's asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).
About IMMX Immix Biopharma Inc.
Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.